Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss

 
• By Alaric DeArment
Travere announced data from the Phase III PROTECT study of Filspari in IgA nephropathy • Source: Shutterstock

More from Clinical Trials

More from R&D